Erasca Stock
Erasca, Inc.
Company data
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- CEO
- Jonathan E. Lim
- Employees
- 103
- Market cap
- $4.7 B
- IPO
- 16/07/2021
Erasca, Inc. is a biopharmaceutical company in the clinical development stage based in the US. The firm is headquartered in San Diego and was founded in 2018. Its primary business focus involves identifying, advancing, and commercializing therapeutic solutions for malignancies propelled by the RAS/MAPK pathway. The…
Company description based on the data provider's company data, AI-assisted, created on 16/10/2026. Not investment advice.
Erasca stock: price history
1D
-10.0%
1W
-16.5%
1M
-12.8%
6M
-29.6%
YTD
+259.9%
1Y
+429.2%
2Y
+369.8%
5Y
-24.8%
10Y
–
Next earnings date
Next earnings date
11/11/2026 (in 25 days)
Volatility around earnings
~8% weaker price swings than usual
Pattern chart
Pattern detected by the Market Jury detector vsqueeze-release-v1.0 on 16/10/26. Not a buy or sell signal.Beta
What does this mean?
Volatility squeeze
BearishPrice swings had compressed unusually tight beforehand (volatility near a low) and are now releasing into a stronger move. Technical analysis views such tight phases as often preceding a bigger move.
Chart patterns are a purely technical signal derived from price action. At Market Jury they do not feed into the agents' buy or sell decisions, they are supplementary information only.
Ask the agents about Erasca
Analyst assessment of Erasca
PRICE TARGET LOW
US$16.00
CONSENSUS
US$22.50
MEDIAN
US$21.50
PRICE TARGET HIGH
US$30.00
0
STRONG BUY
9
BUY
2
HOLD
0
SELL
0
STRONG SELL
11
TOTAL · Buy
As of: 14/08/2026
Erasca stock metrics
P/E
-14.09
P/B
11.52
EV/EBITDA
-16.48
RETURN ON EQUITY
-12.2%
NET MARGIN
0.0%
DEBT/EQUITY
0.12
DIVIDEND YIELD
0.0%
AS OF
30/06/2026
Free float & liquidity
FREE FLOAT
70.7%
FLOAT SHARES
247,182,751
AVG. DAILY VOLUME (30D)
5,266,624
Attention
1 mention today in US forums, about the same as yesterdayPrice since yesterday: -10.0%
Forums (Reddit)
Institutional holders
Comparable stocks
Frequently asked questions about Erasca stock
What does Erasca do?
Erasca, Inc. is a company in the Healthcare sector, Biotechnology industry, headquartered in United States.
The CEO is Jonathan E. Lim, the company employs around 103 people.
The IPO was on 16/07/2021; the stock trades on NASDAQ under the ticker ERAS.
What do analysts say about Erasca stock?
11 analysts rate the stock, the consensus is Buy (as of 14/08/2026).
The average price target is US$22.50, ranging from US$16.00 to US$30.00, with a median of US$21.50.
This is an external assessment, not a statement by Market Jury.
When does Erasca report next?
The next earnings date is 11/11/2026.
Around past earnings, price swings were roughly -8% stronger than usual.
Does Erasca pay a dividend?
No, Erasca currently does not pay a dividend.
Which stocks are comparable to Erasca?
Comparable stocks include Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals, Revolution Medicines, Incyte, Exelixis, Neurocrine Biosciences and Summit Therapeutics.
How can I get Erasca stock analyzed?
Clicking "Analyze stock" lets five strategies assess Erasca against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.